● Pharmacogenetics
-
Munhu CYP2C9 uye VKORC1 Gene Polymorphism
Kiti iyi inoshanda kune in vitro qualitative diagnosis yepolymorphism yeCYP2C9*3 (rs1057910, 1075A>C) uye VKORC1 (rs9923231, -1639G>A) mune genomic DNA yemasampuli eropa revanhu.
-
Munhu CYP2C19 Gene Polymorphism
Iyi kit inoshandiswa in vitro qualitative kuonekwa kwepolymorphism yeCYP2C19 majini CYP2C19*2 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*2 c685 (rs68, 1485) > T) mune genomic DNA yemasampuli eropa revanhu.
-
Human Leukocyte Antigen B27 Nucleic Acid
Iyi kit inoshandiswa pakuonekwa kwemhando yeDNA mumunhu leukocyte antigen subtypes HLA-B*2702, HLA-B*2704 uye HLA-B*2705.
-
MTHFR Gene Polymorphic Nucleic Acid
Iyi kit inoshandiswa kuona 2 mutation nzvimbo dzeMTHFR gene.Iyo kit inoshandisa ropa remunhu rose seyedzo sampuli kuti ipe hunhu hwekuongorora mamiriro ekuchinja.Inogona kubatsira varapi kugadzira zvirongwa zvekurapa zvinoenderana nehunhu hwakasiyana kubva pachikamu chemolecular, kuitira kuti uve nechokwadi chehutano hwevarwere kusvika pamwero mukuru.
